Phase 2 study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3b) inhibitor, with gemcitabine/nab-paclitaxel (GnP) in first-line advanced pancreatic ductal adenocarcinoma (PDAC).